Osteonecrosis of the jaw among cancer patients in Denmark: risk and prognosis

Data from an analysis of population-based medical registries showed that among 33,975 patients with multiple myeloma or solid tumors who received anti-resorptive treatment, there was a cumulative incidence of osteonecrosis of the jaw (ONS) of 1.9% (95% CI 1.6%-2.3%) at a maximum 7.5-year follow-up. Five-year cumulative incidence, which varied by cancer site, was 1.3% (95% CI 1.2%-1.6%).